Zodasiran
RNA / oligonucleotide
Also known as VSA003
Evidence outlook · registrational
Homozygous Familial Hypercholesterolemia: registrational readout pending
No completed mid-stage readout is on record. Registrational readout expected around 2027-08-20.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
YOSEMITE NCT07037771 · Homozygous Familial Hypercholesterolemia Registry: NCT07037771 | 3 | Percent Change from Baseline to Month 12 in Fasting Low Density Lipoprotein Cholesterol (LDL-C) (Randomized period) (Baseline, Month 12) 2027-08-20 | In progress: results expected 20 Aug 2027 | not yet graded | link ↗ |
View 1 more trial
NCT06712771 NCT06712771 · Homozygous Familial Hypercholesterolemia (HoFH) Registry: NCT06712771 | 3 | Percent change from baseline in serum LDL-C at month 6 2025-12-31 | Results not posted; external-source review pending | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (3)
What this study did
What this study did
What this study did
Phase 2 (2)
What this study did
What this study did
Phase 1 (2)
What this study did
What this study did
Competitive landscape
This drug's own stage for Homozygous Familial Hypercholesterolemia: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Zodasiran: this drug | Phase 3 | RNA / oligonucleotide | ANGPTL3 gene mRNA (hepatic) | not yet graded | No reviewed efficacy summary in this indication | |
| Alirocumab (Praluent) | Approved | Monoclonal antibody | PCSK9 | Partial signal | NCT03156621: Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 12 (Intent-to-Treat [ITT] Estimand) (Baseline to Week 12): Alirocumab 150 mg SC Q2W -26.9 Percentage of change (Standard Error 4.6) vs Placebo in DBTP 8.6 Percentage of change (Standard Error 6.3) | |
| Evinacumab (Evkeeza) | Approved | Monoclonal antibody | ANGPTL3 | Partial signal | NCT03399786: Percent Change in Calculated Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 24 (Intent-to-Treat [ITT] Estimand) (Week 24): Evinacumab 15 mg/kg IV Q4W -47.1% (Standard Error 4.6) vs Placebo IV Q4W 1.9% (Standard Error 6.5) | |
| Evolocumab (Repatha) | Approved | Monoclonal antibody | PCSK9 | Reliable signal | NCT01588496: Part B: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12: Evolocumab -23.05% (Standard Error 3.78) vs Placebo 7.88% (Standard Error 5.26); LS mean treatment difference -30.93% (95% CI -43.86 to -18.00), p<0.001 | |
| Ezetimibe (Zetia) | Approved | Small molecule | Dietary Cholesterol Absorption Inhibitor, NPC1L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Ezetimibe / Simvastatin (Vytorin) | Approved | Small molecule | HMG-CoA reductase / NPC1L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Inclisiran (Leqvio) | Approved | RNA / oligonucleotide | PCSK9 | Partial signal | NCT04659863: Percentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1) (Baseline and Day 330): Part 1- Inclisiran -21.6% (Standard Deviation 13.36) vs Part 1 - Placebo 11.7% (Standard Deviation 30.52) | |
| Lomitapide (Juxtapid) | Approved | Small molecule | MTP | Weak signal | NCT04681170: Efficacy Endpoint: Percent Change in Low-density Lipoprotein Cholesterol (LDL C) at Week 24 Compared to Baseline (Baseline through Week 24): Age 5-10 Years -56.529% (Standard Deviation 26.5401) | Age 11-17 Years -51.633% (Standard Deviation 25.5658) NCT02173158: Percent Change in LDL-C (Baseline to Week 26): Lomitapide -42.2% (Standard Deviation 18.16) | |
| Rosuvastatin | Approved | Small molecule | HMG-CoA reductase | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-1918 | Phase 3 | Monoclonal antibody | ANGPTL3 | Partial signal | NCT06723652: LDL-C -58.8% vs +5.5% with placebo at week 12 (difference -64.2%), ESC 2026 |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Zodasiran to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.